Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

The United States genetic testing market is poised for substantial growth, projected to expand from USD 4.71 billion in 2021 to approximately USD 12.08 billion by 2028, with a robust CAGR of 14.50%.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this ...

The Bureau of Labor Statistics reported Wednesday that February prices for food and services haven’t gone up as much as many experts were expecting.

Ambry Genetics will continue to operate as a wholly-owned subsidiary under its current leadership team. The positive market response also reflects the company's strong performance over the past ...

In February, TEM announced the completion of its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between ...

Other Strategic Acquisitions and Partnerships to Accelerate Growth The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus AI’s genomics capabilities by adding ...